China's health care expenditure is one of the largest in the world and is set to grow strongly in the foreseeable future. A greater understanding of the impact of economic and policy factors on China's health care expenditure and its growth trend will help major pharmaceutical firms make strategic plans in the emerging markets. METHODS: Dynamic least squares regression was used on annual time series data (1970 to 2011). The dependent variable was real per capita health care expenditure (RPCHE). The explanatory variables included real per capita GDP (RPCGDP), relative price for consumer health spending (RPCMED) and lagged variables. The analysis used data from WHO, China Statistical Yearbook and IHS Healthcare Forecasting. The main independent variables were RPCGDP and RPCMED. RESULTS: A negative correlation was found between estimated RPCHE and RPCMED; and a positive correlation between estimated RPCHE and RPCGDP. The main results can be summarized as follows: 1) For every 1% rise in the growth rate of RPCMED, there is a 1.16% decrease in the level of RPCHE, and 2) the income elasticity of real health care expenditure is 15%. Based on the estimations, forecasts on total health care expenditure were made for the forecast period (2012-2020). The main independent variables-RPCMED and RPCGDP-were derived from IHS Macro for the forecast period. To capture health care policy's impact on health care expenditure, add factors were used in the forecast. According to the forecast, China's total health care expenditure is projected to grow 15.8% this year and 14.8% next. CONCLUSIONS: In terms of economic impact, relative price for consumer health spending and income play a major role in determining health care expenditure. In terms of policy impact, China's health care reform-via massive health insurance expansion-will be a key driver of health care expenditure growth throughout the forecast horizon, although there are increasing pressures on pricing and significant regional disparities.
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DOWN-SCHEDULING MEDICINES FROM PRESCRIPTION TO OVER-THE-COUNTER: WIN-WIN?
Priest VL, Tan SC Double Helix Consulting, Asia-Pacific, Singapore, Singapore OBJECTIVES: Each year over a million patients in Australia delay seeing a General Practioner (GP), and a similar number do not fill their prescriptions, because of the cost. This failure to access necessary medications has economic and morbidity implications in the long-term. In addition, reduced uptake affects company revenue. Currently the US Food and Drug Administration (FDA) is considering a range of measures to improve access to medicines, including making more drugs used for common, under-treated conditions, available over-the-counter (OTC). This study aimed to compare the costs to the patient and potential manufacturer price for a sample of medicines that are available both OTC and on prescription in Australia. METHODS: Costs of accessing diclofenac (25mg tablets) and omeprazole (20mg tablets) via a GP prescription were compared to those for OTC. For medicines obtained on prescription, patient co-payments were sourced from the Pharmaceutical Benefits Schedule (PBS) website, and the average cost of a GP visit. Costs of OTC formulations were estimated based on a sample of pharmacies. The resultant cost to patient and potential price to the manufacturer were calculated and compared. RESULTS: For patients in Australia, OTC acquisition of medicines was up to 50% less expensive per tablet than accessing treatment via GP prescription. The pertablet savings for patient were greater for omeprazole than for diclofenac. At the point of sale, the cost per tablet of OTC products was 150%-500% of the ex-manufacturer cost for the PBS listed product. Therefore, an OTC strategy also appears to be a commercially viable for manufacturers, even allowing for a pharmacy mark-up. CONCLUSIONS: Down-scheduling from prescription-only to OTC may decrease the direct costs of treatment for patients, while simultaneously increasing the price per tablet to manufacturers: a win-win situation.
PHP50 INTEGRATED CLOSED INTRAVENOUS CATHETER SYSTEM REDUCES THE OCCURRENCE OF THE CATHETER REPLACEMENT AND THE COST
Tamura N 1 , Abe S 1 , Hagimoto K 1 , Kondo A 1 , Matsuo A 1 , Ozawa Y 1 , Takahashi M 1 , Yokokawa S 1 , Kuri J 2 , Tateno H 2 , Tomaru T 2 1 Koto Hospital, Tokyo, Japan, 2 Nippon Becton Dickinson Company, Ltd., Tokyo, Japan OBJECTIVES: Replacement of Peripheral Venous Catheter (PVC) is sometimes required prematurely due to extravasation, catheter damage, complications such as phlebitis. We evaluated the clinical and economic benefits of an integrated closed intravenous catheter system (CICS) with pre-attached stabilization platform and extension tube (Catheter A) which may reduce the occurrence of unscheduled catheter replacement. METHODS: A prospective, open, quasi-random, and controlled study was conducted to compare Catheter A and a conventional PVC (Catheter B) in a 286-bed general hospital in Japan. Patients requiring PVCs for 72 hours or more were enrolled and assigned to either Catheter A Group (Group A) or Catheter B Group (Group B). Both catheters were secured with the same procedure and regularly observed until removal. The Kaplan-Meier estimate for the replacement rates for both catheters for 72 hours was calculated, and the cost difference between the groups was obtained using product prices and average nursing fees published by the government. RESULTS: There were 358 patients evaluated: 193 in Group A and 165 in Group B. One hundred forty three patients in Group A and 109 patients in Group B required catheter replacement because of extravasation, catheter damage, complications, or scheduled catheter removal. The remaining 106 patients from both groups had catheters removed for unexpected reasons such as earlier end of therapy and self-withdrawal. Excluding those 106 patients, there was a significant difference in the catheter survival curves between Group A and B (pϽ0.01, log-rank test). The total cost of catheter replacement for 72-hour use was 393 yen for Group A and 704 yen for Group B. CONCLUSIONS: The cost difference between two catheters can be offset by savings generated from a lower event rate. Along with total cost benefits, the use of CICS is considered to provide improved safety to patients through decreased complications.
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MANAGEMENTS OF FEBRILE NEUTROPENIA AMONG NON-HODGKIN'S LYMPHOMA PATIENTS IN TAIWAN
Lin WT 1 , Hsiao FY 1 , Chiang SC 2 , Wen YW 3 1 National Taiwan University, Taipei,Taiwan, 2 Koo Foundation Sun Yat-Sen Cancer Center, Taipei,Taiwan, 3 Chang Gung University, Taoyuan,Taiwan OBJECTIVES: Febrile neutropenia (FN) is a major complication in cancer patients treated with chemotherapy, leading to infection-associated morbidity and mortality. Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is recommended by recent clinical guidelines to manage those patients with high risk of FN. Uncertainty in selecting patients who need G-CSF prophylaxis, however, remains in clinical settings. The objectives of this study were to document the utilization pattern of G-CSF and to analyze the potential risk factors of FN in non-Hodgkin's lymphoma (NHL) patients. METHODS: Eligible patients were those who were older than 18 years, diagnosed with NHL, and initiated a new chemotherapy regimen in 2010 at a medical center in Taiwan. All chemotherapy cycles received by our study subjects were divided into two groups based on the occurrence of FN during each cycle. All patients were followed until all the planned chemotherapy courses were completed or one year after the first date of chemotherapy regimen. Differences in patient characteristics between the FN and non-FN group were assessed with chi-square tests for categorical variables and t-tests for continuous variables. RESULTS: Two hundred and eighty-six courses for G-CSF prophylaxis were evaluated in 72 patients receiving a total of 432 cycles of chemotherapy regimen. Of these, 38 % of G-CSF was prescribed as primary prophylaxis, and 62 % as secondary prophylaxis, with an average duration of 3 days. Differences between FN and non-FN group which is statistically significance were history of chronic renal failure or anemia (pϭ0.0038, pϽ0.0001), prophylactic use of G-CSF (pϭ0.0192), performance status (pϭ0.0001), numbers of previous neutropenia (pϭ0.0008), baseline albumin or hemoglobin level (pϭ0.0085, pϽ0.0001). CONCLUSIONS: At this cancer center in Taiwan, the duration of G-CSF administration is shorter than the recommended. Differences between the two groups may be the possible risk factors, and need to be further analyzed. 
PHP53 COMPARATIVE EVALUATION OF DRUG INFORMATION SOURCES USED BY DOCTORS
OBJECTIVES:
To compare pharmaceutical company and medical representatives as drug information source with other conventional and advanced sources being used by Doctors. METHODS: A total 103 doctors were interviewed personally by using a structured validated questionnaire developed. Ransom and purposeful sampling was used to select the required sample. The data collected was evaluated and represented in the form of total numbers and percentages. RESULTS: Among 103 doctors (52.42% or 54) mentioned that pharmaceutical companies and medical representatives are less useful source of information. 58.25% doctors responded that Pharmaceutical company sponsored Education program as useful. A total of 17.47% mentioned it as very useful source of information for new drugs and 24.27% doctors mentioned it as less useful. A total of 59.12% doctors mentioned medical A618 journals and articles as very useful source of information and 35.92% doctors mentioned as useful source of information. Only 4.85% doctors believe this is less useful source of drug information. 49.51% of doctors believe as very useful source of information and 45.63% as useful. Only 4.85% doctors mentioned that as less useful source. Subscription based source showed that 41.74% doctors mentioned that as very useful source and 49.51% mentioned that as useful source. A total of 8.73% doctors mentioned that as less useful source. Informal discussions with other doctors as drug information source is very useful for 47.57% doctors and useful for 46.60% while only 5.82% doctors mentioned that as less useful source of information. CONCLUSIONS: Medical representative is not the option for successful promotion, companies should also focus on other sources ex. medical journals, internet sources which are highly appreciated among health care practitioners.
PHP54 CHEMICAL DRUG PRICE INDEX STUDY
Chang F 1 , Zhu D 2 , Zhao Z 3 , Yang Z 3 1 Research Center of Drug Pricing, China Pharmaceutical University, Nanjing, Jiangsu, China, 2 China Pharmaceutical University, Nanjing, Jiangsu, China, 3 China Price Association, Beijing, Beijing, China OBJECTIVES: To accurately reflect actual price level of chemical drugs and changes, this study deeply explored influencing factors of chemical drug price, constructed chemical drug price index system and meanwhile sought methods to establish price index of a specific type of chemical drugs. METHODS: Combination of qualitative and quantitative methods was used to explore establishment of chemical drug price index. Expert evaluation and field survey were used to determine classification of chemical drugs, representatives and representatives' weights. Questionnaire was used to determine key data in selection of chemical drug representatives. Field survey was used for data collection. RESULTS: On the basis of chemical drug classification, representatives were determined step by step. By collecting chemical drug price data in representative regions and manufacturers, quantitative calculation of weight was performed. Selection route of quality adjustment method and key quality collection method when representative changed in price index were investigated. Data collection protocol required to establish chemical drug price index was proposed. Feasibility to establish chemical drug price index system was explored and several main price indexes were proposed. CONCLUSIONS: First, this study proposed specific methods to establish chemical drug prices and solved the problem of selecting representative from various chemical drugs. Second, quality adjustment decision process was proposed and key quality adjustment methods were explored. Finally, as it is difficult for a single overall chemical drug price index to completely reflect the general view of chemical drug price level and changes in our country, this study proposed an index system including overall index, essential drug index and antibiotic index based on the need of reality.
PHP55 PERCEPTION TOWARDS HEALTH PROMOTION ACTIVITIES: FINDINGS FROM A CROSS SECTIONAL SURVEY AMONG URBAN POOR POPULATION IN THE STATE OF PENANG, MALAYSIA
Hassali MA 1 , Shafie AA 1 , Saleem F 1 , Chua GN 2 , Atif M 3 , Masood I 2 , Haq N 1 1 Universiti Sains Malaysia, Penang, Malaysia, 2 Universiti Sains Malaysia, Penang, P. Penang, Malaysia, 3 Universiti Sains Malaysia, Penang, P.Pinang, Malaysia OBJECTIVES: To provide information on the perceptions towards health promotion activities among an urban poor population of Malaysia. METHODS: The study was designed as a questionnaire based cross-sectional analysis. General public from the district of Jelutong which is located in the state of Penang, Malaysia was conveniently approached for the study. The questionnaire asks about perceptions and awareness towards health promotion activities. Descriptive statistics were used to ascertain demographic characteristics of the study participants. Inferential statistics were employed to measure the extent of association among study variables. All analysis was performed by SPPS v.16.0. RESULTS: Out of 480 respondents, a response rate of 82.7% was achieved as 397 responded to the survey. The study cohort was dominated by females (63.0%). Majority of the participants belonged to Malay ethnicity (88.1%). One hundred and seventy two (43.3%) never attended a health promotional campaign and mentioned lack of time and transport as potential barriers. Among those who attended such activities, one third was satisfied with the benefits of health campaigns and indicated an improvement in their quality of life. Approximately 90% of the participants demanded accessible locations, common language as mode of communication and complete medical checkup with professional advice at health promotional campaigns. CONCLUSIONS: Almost half of the study population never attended a health promotional campaign. General public should be educated and encouraged to participate in the health promotion activities. In addition, potential barrieers like lack of time and transport should be avoided by organizing such events with the reach of the community members.
PHP56 THE ROLE OF ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IN WORKS AND RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN YEARS 2005-2011
Ofierska-Sujkowska G, Matusewicz W, Jagodzinska-Kalinowska K Agency for Health Technology Assessment in Poland (AOTM), Warsaw, Poland OBJECTIVES: To assess the influence and role of antineoplastic and immunomodulating agents in works and recommendations of AOTM. The main role of AOTM, established in 2005, is to assess, appraise and prepare recommendations on financing all medical technologies and services claiming public money founding. Full pharmacoeconomic evaluations of new therapies are required for all reimbursement decisions. Manufacturers of antineoplastic and immunomodulating drugs are obligated to provide HTA reports in order to have their drug reimbursed. Recommendations issued by AOTM have been based on Manufacturer's submission, additional published data, experts and Polish public payer opinions. METHODS: All recommendations issued by the AOTM until the end of 2011 were reviewed and analyzed from the official website of AOTM. The recommendations related to antineoplastic and immunomodulating drugs were distinguished. RESULTS: Among 400 AOTM recommendations analyzed, the largest number, 142 of 400 (36%) was connected with antineoplastic and immunomodulating agents. 105 (74%) of them regarding oncology treatment. Recommendation for non-drug technologies were issued to 47 (12%) of 400 technologies. 58 (15%) applied to drugs used in the treatment of nervous disorders, 34 (9%) metabolic disorders, 31 (8%) were related to cardiovascular drugs, 21 (5%) genito-urinary system. 15% of verified documentations applied to other, single indications. CONCLUSIONS: The number of recommendations issued for antineoplastic and immunomodulating drugs in comparison to other medicines reflects the importance and significance of this area of medicine. Documents prepared by AOTM related to antineoplastic (cancer chemotherapy) treatment represent standards and trends in contemporary medicine.
PHP57 CLINICAL EFFECTS OF PHARMACIST INTERVENTIONS FOR POLYPHARMACY IN A GERIATRIC CLINIC IN TAIWAN
